Hormonal
Thiazolidinediones (PPAR-gamma agonists) improve insulin sensitivity and beta-cell function by enhancing adipocyte insulin sensitivity, inhibiting lipolysis, reducing plasma FFA, and redistributing fat away from visceral and hepatic depots to subcutaneous fat.
Thiazolidinediones (TZDs) are a class of diabetes medications that work by improving the function of fat cells. They help store fat in the right places (subcutaneous) rather than harmful places (liver, muscle), which reduces the toxic free fatty acids that cause insulin resistance. This improves how the body uses insulin and protects the pancreas.
Thiazolidinediones enhance adipocyte insulin sensitivity, inhibit lipolysis, reduce plasma FFA, and favorably influence the production of adipocytokines. Thiazolidinediones also redistribute fat within the body (decreased visceral and hepatic fat; increased sc fat) and decrease intracellular concentrations of triglyceride metabolites in muscle, liver, and beta-cells...
Why this rating
The paper cites clinical evidence and mechanistic studies supporting the redistribution of fat and improvement in insulin sensitivity.
Source
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
Harold Bays et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2003-030723
More from this paper
- Chronically elevated plasma free fatty acid (FFA) levels cause insulin resistance in muscle and liver and impair insulin secretion in pancreatic beta-cells, a process termed lipotoxicity.Strong
- Dysfunctional adipocytes in T2DM produce excessive insulin-resistant and inflammatory cytokines (e.g., resistin, TNF-alpha, IL-6, PAI-1) and secrete reduced amounts of insulin-sensitizing adipocytokines (e.g., adiponectin).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →